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 Figure 1: a) Effective doses and b) LYL-ratios. 
 
Conclusions: The LYL attributable to cancer therapy were orders of 
magnitudes larger than the LYL attributable to the diagnostic scans 
used for radiotherapy planning. However, the uncertainty in the 
present estimates of LYL were considerable, and would benefit from 
more exact risk models.  
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Purpose/Objective: Patient-(age, performance status, psychological 
distress), disease-(type, localization) and treatment (neurosurgery, 
radiotherapy, chemotherapy)-related factors may impact on cognitive 
functioning of metastasis patients. Neuropsychological involvement 
may be an important factor, reducing quality of daily life (QoL). This 
study aimed to evaluate difference between whole brain radiotherapy 
(WBRT) and radiosurgery (SRS) on neurocognitive functioning 
accordingly on QoL of brain metastasis patients. We did a randomized 
controlled trial to test our prediction. 
Materials and Methods: Patients with solitary brain metastasis of solid 
tumors with stable systemic disease tumors and KPS >/= 70 were 
treated with complete surgery and randomly assigned to adjuvant 
WBRT (30 Gy in 10 fractions) or SRS (17-20 Gy single fraction) on 
surgical cavity (max diameter 3.5 cm). The primary end point was 
local control, secondary end points survival, quality of life and 
toxicity. 65 patients, fulfilling the study inclusion criteria, were 
treated since December 2009 to September 2012. After randomization 
42 subjects were assigned to SRS group, 23 to WBRT. All subjects were 
tested to assessed global cognitive functioning using the Mini Mental 
State Examination (MMSE): at baseline (T1) before radiotherapy 
treatment, after one year (T2) and after 2 years (T3). Preliminary 
results were available for 55 subjects at T1, for 25 subjects at T2, for 
6 at T3. 
Results: The pretreatment MMSE was available for 37 patients 
randomized for SRS, and 18 for WBRT. The sample did not present 
cognitive deficit post surgery and no statistically significant difference 
were found between the baseline MMSE of two groups (P = 0,064). Of 
the 25 patients underwent the follow–up MMSE at one year, 10 (40%) 
had improved their scores and 5 (20%) worsened in SRS group; all 
subjects (100%) obtained lower scores in WBRT group. From 
preliminary evaluations it was found a statistically significant 
difference between the neurocognitive performance of WBRT group 
and the SRS one (P = 0,039). Currently, there’s no sufficient data at 2 
years. 
Conclusions: The results of this study have revealed that the long – 
term adverse effect of WBRT on neurocognitive functioning might not 
be negligible also for the quality of life of brain metastases patients.  
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Purpose/Objective: Many studies have assessed the fractionation 
scheme to choose the most appropriate in individual cases. Various 
fractionation schemes can provide a response equivalent to the 
control of pain, although longer treatment has the advantage of a 
lower incidence of reprocessing the same site. The aim of our 
retrospective study was to evaluate the differences in requirements 
and the impact of different radiotherapy schedules on patients 
symptoms in relationship to primary tumor type and quality of life. 
Materials and Methods: We analyzed 458 treatments of palliative 
radiotherapy for bone metastases. For these patients, we did control 
of pain, performance status and pain-therapy, before treatment, after 
treatment, and 180 days after the end of treatment. We analyzed the 
data using the T-test for paired data and the ANOVA test and we 
performed a comparison of performance status and pain in relation to 
the type of fractionation. 
Results: We noticed an improvement in performance status and pain 
relief in all groups, but the pain improvement was more evident in 
patients treated with single fraction, while we noticed a difference of 
the average KI before and after RT, even if not statistically 
significant, in favor of the longest fractionation (30 Gy) schemes. We 
also have focused our attention in patients with primary tumors with 
expected greater overall survival, in particular, we considered 
patients treated for bone metastases from breast cancer. The 
differences between averages with ANOVA test seemed to 
demonstrate an advantage in favor of the 30Gy schedule for the KI (ns 
p = 0.105), while they were favorable to the single fraction of 8 Gy for 
the NRS (p <0.001). 
Conclusions: We have obtained data which are in line with the 
statement made in recent years on the equivalence of the various 
types of fractionation for the control of pain from bone metastases, 
but that suggest a greater attention to the radiation oncologist in the 
choice of the patient to be subjected to various types of 
fractionation. It is recommended to put a considerable amount of 
attention over which the clinical condition of patients, the primary 
tumor (breast) of patients who, for the greater life expectancy 
resulting from the natural history of cancer, should have a better 
access to a more prolonged treatment. 
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Purpose/Objective: This retrospective analysis reports the outcomes 
obtained with an original once weekly stereotactic radiotherapy 
fractionation delivered for patients affected by evolving 
oligometastases from different solid malignancies. 
Materials and Methods: From 2009 to 2011 patients with symptomatic 
and/or evolving oligometastases were submitted to a median 5-
fraction-cycle of stereotactic radiotherapy by delivering only one a 
fraction per week in order to exploit a radiobiological rationale 
designed to increase the therapeutic index. Individual fractionation 
was mainly planned according to patient performance status, 
oligometastases size and site and record of previous irradiation in the 
same site. 
Results: Thirty-six patients in stage IV UICC-TNM affected by 
oligometastases were treated with image-guided/intensity modulated 
stereotactic tomotherapy by delivering a single weekly radiation. 
Median age was 70 yrs (34-89 yrs). The median weekly single dose, 
number of fractions and overall total radiation dose were 7 Gy, 5 
fractions and 35 Gy, respectively. Thirty-five (97%) patients 
completed the treatment schedule. No patient suffered mild or severe 
radiation-related side effects. Twenty-one (87%) out of 24 patients 
with local pain had complete symptomatic response within 30 days 
from the end of radiotherapy. Local control assessed at imaging after 
SRT was evidenced in 30 (83%) of patients. Median time to response 
after the end of radiotherapy was 40 days . 
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Conclusions: This original radiotherapy regimen delivering only a 
single stereotactic dose per week seems to be highly feasible with an 
interesting high rate of efficacy for patients with oligometastases 
from different solid tumors. Overall, the once weekly treatment is 
very compliant in advanced cancer stage especially for elderly and 
frail patients. 
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Purpose/Objective: To retrospectively evaluate external beam re-
irradiation (re-EBRT), delivered to the prostate or prostatic bed for 
local recurrence after radical or post-operative/salvage radiotherapy. 
Materials and Methods: 17 pts have been treated with re-EBRT at our 
Department between 2/2008 and 8/2012. Previously RT included 
radical RT 13 pts (12 pts with EBRT and 1 pt with brachytherapy, post-
operative RT (2 pts) or salvage RT (1 pt), 1 pt not reported. All pts 
had local relapse in the prostate or prostatic bed with no distant 
metastasis: biopsy was performed in all but 1 pts, and all the pts had 
total body computer tomography (CT) or 11C-choline positron emission 
tomography scan. One pt. was previously treated also with 3D-CRT for 
lymph node recurrence with complete remission.  
The mean age, iPSA and Gleason Score (GS) at diagnosis were 61 yrs 
(49-67), 15 ng/ml (4.57-67) and 6 (4-9), respectively.  
The re-EBRT technique included 3D IGRT, stereotactic RT, IMRT, 
stereotactic RT + IMRT, CyberKnife respectively in 1,8,6,1,1 pts. The 
following schedules were employed: 25 Gy/5 fr(12 pts), 30 Gy/6 fr(4 
pts) and 15 Gy/3 fr (1 pt). Four pts were included in a previous study.  
Concomitant hormonal therapy (HT) was administered in 7 pts. 
Toxicity and tumor response were evaluated using Radiation Therapy 
Oncology Group/European Organization for Research and Treatment 
of Cancer and Response Evaluation Criteria In Solid Tumors criteria. 
Biochemical and clinical response, using radiologic criteria, was also 
registered.  
Results: Acute toxicity included: 3 G1, 1 G2 genitourinary events; 1 
G1, 1 G2 gastrointestinal events. Late toxicities (> 6 months of f.u., 
data available in 9 pts): 5 pts with no toxicity; 2 G1 gastrointestinal 
and 1 G1 genitourinary events respectively.  
The mean interval between the primary treatment and the clinical 
local relapse was 64 months, and the mean follow-up after re-EBRT 
was 24 months (5-30). Two pts died for the prostate cancer 
progression at distant sites: the interval between re-EBRT and the 
death was 30 mo. for each. The remaining 15 patients are alive: 12 
with no evidence of disease and 3 pt is alive with disease in clinical 
control with HT. 
Conclusions: In our single institution preliminary experience re-EBRT 
of local relapse of the prostate cancer appears feasible and well 
tolerated. Local control was excellent (non local recurrence was 
registered within mean follow-up of 2 years) and 70% of patients alive 
with non evidence of disease. Longer follow-up and bigger patient 
series is warranted in order to confirm these promising early findings.  
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Purpose/Objective: While research in the physics domain for 
Flattening Filter Free Beams (FFF) beams is increasing, there are few 
clinical data of FFF beams in clinical practice. Here we reported early 
clinical results of SBRT and FFF delivery in isolated lymph node 
oligometastatic patients. 
Materials and Methods: Between October 2010 and March 2012, 34 
patients were treated with SBRT for oligometastatic lymph node 
metastasis using Volumetric Modulated Arc Therapy (RapidArc on 
Truebeam platform). We retrospectively evaluated a total of 25 
patients for isolated lymph node metastases in abdomen and/or pelvis 
treated with SBRT and FFF (28 treatments). Prescription doses were 
45 Gy in 6 consecutive fractions of 7.5 Gy for all 28 treatments. The 
inclusion criteria were: age≥18years, WHO performance status ≤ 2, 
histologically-proven of primary cancer disease, M1 stage with primary 
cancer site radically treated with complete response/resection or 
stable, no other site of disease in progression (amaximum of 3 lymph 
node sites of disease to treat), diameter of lymph node Target less 
than 5 cm, Abdomen/pelvic site, no previous surgery or RT in the 
region to treat, obtained informed consent. Chemotherapy, when 
prescribed, was interrupted from 20 days before the simulation to the 
first evaluation after the end of SBRT treatment, as scheduled. Acute 
toxicity was recorded and scored according to CTCAE v.4. Local 
control evaluation was scored by means of CT scan and/or PET scan, 
according to PERCIST criteria. 
Results: All 25 FFF SBRT patients completed the treatment. Acute 
gastrointestinal toxicity was minimal: one patient showed Grade 1 
gastrointestinal toxicity.Three other patients presented Grade 2 
toxicity. No Grade 3 or higher was recorded. All toxicities were 
recovered within one week. The preliminary clinical results at the 
median follow up of 195 days are: complete response in 12 cases, 
partial response in 11, stable disease in 5, with an overall response 
rate of 82%; no local progression was recorded.  
Conclusions: Data of acute toxicity are excellent for patients treated 
with SBRT with VMAT using FFF beams. Preliminary clinical results 
showed a high rate of local control in irradiated lesion. Further data 
and longer follow up are needed to assess late toxicity and definitive 
clinical outcomes. 
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Purpose/Objective: Cancer-Associated Fibroblasts (CAFs) are major 
components of solid malignancies and play central roles on cancer 
sustainability. In the context of radiotherapy, collateral effects of 
ablative ionizing radiation (AIR) on stromal components of tumors 
remain understudied. In this work we have examined the impact of 
AIR on CAFs from human lung tumors.  
Materials and Methods: CAFs prepared from resected human lung 
tumors were exposed to AIR (1x18Gy). Intrinsic radio-sensitivity was 
evaluated by checking viability and extent of DNA-damage responses 
at scalating radiation doses. Proliferation, migration and invasion 
rates were monitored in label-free assays by xCELLigence system. 
Inflammatory mediators, as well as regulators of angiogenesis and 
tumor growth were analyzed by multiplex protein assasy in 
conditioned medium (CM) from irradiated and control CAFs. 
Additionally the entire secretory protein profile was examined by 
mass spectometry. In functional assasys, the potential effects of CAFs 
released factors on the proliferative and migratory capacity of lung 
tumor cell (H520 and H522) and on endothelial cells (HUVEC) was also 
investigated. 
Results: Our results show that CAFs survive ablative doses of 
radiation, but cells enter a senescent state associated with reduced 
proliferation and invasion. A lowered MMP-1 expression and the 
stabilization of focal contacts via integrins were responsable 
mechanisms behind the reduced cell motility. On the other hand, 
analyses of the secretory profile revealed a reduced expression of 
angiogenic factors like SDF-1a and TSP-2, and altered expression of 
tumor regulators such as bFGF, PEDF and MIF upon radiation. No 
prominensignificant differences were observed on the behaviour of 
tumor cells or endothelial cells exposed to irradiated and control CAF-
CM 
Conclusions: AIR provoked a reduction in the proliferative and 
migratory abilities of CAFs, along with a transformation of their 
secretory profile. These radiation-induced chages on tumor resident 
fibroblasts could influence the behaviour of adjacent cells in the 
tumor tissue and hence influence therapeutic outcomes. Downstream 
consequences of the changes observed in this study merits further 
investigations.  
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